

**Mouse Anti-HPV 16 [CAMVIR-1]: MC0801, MC0801RTU7**

**Intended Use:** For Research Use Only

**Description:** The antibody reacts with a 56 kDa protein in cells infected with L1-vaccinia virus, the protein being present in a predominantly nuclear location. The antibody reacts very strongly with biopsy specimens containing HPV-16 or -33; very weak reactions were occasionally observed with biopsy specimens or smears containing HPV-6 or HPV-11. Cross-reacts with HPV37.L1 is a major capsid protein of type 16 human papilloma virus. Infection with specific types of HPV has been associated with an increased risk of developing cervical neoplasia. HPV types 6 and 11 have been associated with relatively benign diseases such as genital warts but types 16 and 18 are strongly associated with cervical, vaginal, and vulvar malignancies.

**Specifications:**

Clone: CAMVIR-1  
Source: Mouse  
Isotype: IgG2a/k  
Reactivity: Human  
Immunogen: Human papilloma virus type 16, major capsid protein L1  
Localization: Virion, host nucleus  
Formulation: Antibody in PBS pH7.4, containing BSA and  $\leq 0.09\%$  sodium azide (NaN<sub>3</sub>)  
Storage: Store at 2°- 8°C  
Applications: IHC, ELISA, ICC/IF, IP, WB  
Package:

Description	Catalog No.	Size
HPV 16 Concentrated	MC0801	1 ml
HPV 16 Prediluted	MC0801RTU7	7 ml

**IHC Procedure\*:**

Positive Control Tissue: Cervical cancer  
Concentrated Dilution: 50-200  
Pretreatment: Tris EDTA pH9.0, 15 minutes using Pressure Cooker, or 30-60 minutes using water bath at 95°-99°C  
Incubation Time and Temp: 30-60 min @ RT  
Detection: Refer to the detection system manual  
\* Result should be confirmed by an established diagnostic procedure.



FFPE human cervix stained with anti-HPV16 using DAB

**References:**

1. Expression of P16 in high-risk human papillomavirus related lesions of the uterine cervix in a government hospital, Malaysia. Krishnappa P, et al. Diagn Pathol 9:202, 2014.
2. A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies. Day PM, et al. Clin Vaccine Immunol 19:1075-82, 2012.
3. Human papillomavirus-like particles vaccine efficiently produced in a non-fermentative system based on insect larva. Millán AF, et al. Protein Expr Purif 74:1-8, 2010.

Doc. 100-MC0801  
Rev. A